Kalorama Information is a dependable resource for information on opportunity in the pharmaceutical market. The pharma industry has seen important developments in the last few years, bringing both challenges and new opportunities. The industry outlook for many manufacturers has changed due to outsourcing in drug discovery, growing generic competition and greater interest in biotechnology, among other developments. Our reports provide the sales data, revenue forecasts, and competitive analysis that one needs to understand the market.
Vaccines
Drug Delivery
Over-the-Counter
Drug Discovery
Cancer Treatment
Manufacturing & Packaging
Prescription Drugs
- Sort by Product ID
- Display 15 Products per page
Published: January 1, 2003 | Price: $2,500.00 – $5,000.00
Antibiotic development has never proceeded at this pace or with this much urgency. Demand for effective antibacterial compounds is growing rapidly and companies are trying to fill their pipelines with products that can meet the challenges of increasingly stubborn infectious agents. By far the largest of the anti-infective segments, antibacterials represent approximately 65% of the $20 billion world market in infectious disease drugs. However, it’s also the most crowded of the segments with big pharma and small biotech companies alike...Published: January 1, 2003 | Price: $1,121.00 – $1,717.00
In the summer of 2002, Kalorama Information released a major study on non-psychiatric neurotherapeutic drug markets. At almost 500 pages, the resulting report covered a broad range of neurological agents comprehensively and in depth; however, the breadth and authority of the results proved to be more information than some marketers needed. Smaller biopharmaceutical concerns—some of the real drivers of this market—are more focused on individual neurological disorders such as multiple sclerosis, Alzheimer’s disease, or neurological cancers, rather than the broad...Published: March 1, 2003 | Price: $2,812.00 – $5,625.00
During the last 25 years, there have been unprecedented advancements in the area of women’s health and there is widespread recognition of the importance of addressing conditions that overwhelmingly affect women. Likewise, pharmaceutical marketers have increasingly understood the potential that the women’s health market represents and the increasing clout female consumers are wielding in the prescription drug marketplace. Women’s Health: Worldwide Prescription Drug Markets is a comprehensive study of the pharmaceutical markets aimed at diseases and conditions that affect women....Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
This report analyzes the world markets for human antiviral medications, focusing on the current market for and the development of drugs that are used to directly combat and treat viruses viral infections. For the purposes of this report, antivirals are drugs used to directly treat viral infection after it occurs. The report does not discuss products for the prevention of viral infection—that is, adult or pediatric vaccinations—and does not discuss other diseases, such as cancer or heart disease, that may...Published: April 1, 2003 | Price: $6,000.00 – $12,000.00
Once a public health problem pegged for easy elimination, infectious diseases continue to be the leading cause of death worldwide. Despite improved methods of treating and preventing infection, including potent antibiotics, comprehensive immunization, and modern sanitation, infection still accounts for much serious illness, even in highly industrialized countries. Use this new Kalorama Information 3-volume series to evaluate your organization's position in the highly active anti-infectives market. Volume I Abstract The World Market for Antifungal Medications The market for pharmaceuticals targeted...Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the effectiveness of PTCA. To improve on this condition, medical science created stents in an attempt to keep coronary arteries open. However, one of the early...Published: May 1, 2003 | Price: $2,062.00 – $4,152.00
The number and scope of drug discovery outsourcing agreements has grown rapidly over the past five years, and the pace will accelerate over the next five years. Outsourcing is now an essential part of drug discovery. Major pharmas and biotechs are aggressively pursuing a range of outsourcing agreements. On the supplier side, smaller vendors rely on outsourcing revenues to pay their bills and boost their credibility. Outsourcing in drug discovery is a popular topic for trade articles and seminars. These...Published: May 1, 2003 | Price: $2,625.00 – $5,250.00
Switching dosages and ingredients of prescription medicines to the over-the-counter market is not new. In the past 30 years, more than 70 switches have produced hundreds of brands competing in the consumer market, and the pace promises to accelerate. Going OTC is one of a number of strategies marketers can use to extend the revenue life of their products. Appropriately coordinating the switch with patent expiry, creating coherent branding strategies, and knowing the clinical consumer climate are all factors in...Published: July 18, 2003 | Price: $2,625.00 – $5,250.00
Drug delivery technologies continue to be a vital piece of the pharmaceutical marketing puzzle. From clinical efficacy to product differentiation and life-cycle management, delivery technologies are increasingly demanding the attention of developers at earlier and earlier stages. In Kalorama’s 2001-2002 Drug Delivery series, we focused on the markets by route of administration—oral, injectable, implantable, pulmonary, transdermal etc. In this all new study on advanced drug delivery, however, we focused on drug delivery through the lens of therapeutic application. This report...Published: August 1, 2003 | Price: $2,625.00 – $5,250.00
This Kalorama Information report—Men’s Health: The World Market for Current and Emerging Drug Therapies—focuses on treatment segments in which men are affected. These segments include: · Men’s Cancer · Sexual Function · Sexually Transmitted Diseases · Urinary Conditions · Andropause The report covers drugs that are used for the treatment of conditions affecting men, including prostate cancer, impotence, and BPH; and areas where diseases and men’s health are a major concern including HIV, herpes, and urinary incontinence. Revenues for product...Published: August 1, 2003 | Price: $1,496.00 – $2,992.00
The OTC women’s health market encompasses a wide variety of products that have been determined safe and effective as over-the-counter products. The market is driven by several factors including increasing number of baby boomers entering old age, increasing incidences of diseases; product demand; and several others. In response to many inquiries from readers of Kalorama Information’s March 2003 publication Women’s Health: Worldwide Prescription Drug Markets, 3rd Edition, we embarked on a supplemental study that goes beyond the prescription market to...Published: October 1, 2003 | Price: $2,625.00 – $5,250.00
Growth factors are gene products that play important roles in the regulation of cell division and tissue proliferation. Generally, the binding of a growth factor to its receptor initiates or, in some cases, blocks the ability of cells to divide and multiply. The nature and mode of action of these substances have made them of great interest in various therapeutic areas for which efficacy and specificity must go hand in hand. This report analyzes the world markets for growth factors,...Published: November 1, 2003 | Price: $1,875.00 – $3,750.00
The process of creating a new drug is lengthy and complex. From discovery to development to market, there are numerous pitfalls. In this report, Kalorama focuses on one of the trickiest yet also most promising areas: the interface between discovery and development known as lead optimization. The pressure is on: get better lead compounds faster and at less cost. The amount of money wasted on leads that fail is excessive. And the attrition rate to get a lead is huge....Published: November 1, 2003 | Price: $2,246.00 – $4,492.00
Rheumatoid arthritis is a progressive disease of the joint structure that may be localized or systemic. It varies significantly in severity, producing symptoms that range from minor aches to severe disability and joint deformity. While rheumatoid arthritis can be diagnosed at any age, for childhood to the later years, it most commonly presents with significant symptoms at about middle age. From that point, the disease can progress quickly, slowly or virtually not at all. With an aging population, the unmet...Published: November 7, 2003 | Price: $746.00 – $1,492.00
Over the past three years, Kalorama Information's analysts have studied drug delivery markets from several angles. In 2001 and 2002, we published a 5-volume series on drug delivery technology, each volume devoted to a route of administration: Volume I: Oral Drug Delivery Volume II: Injectable and Implantable Drug Delivery Volume III: Pulmonary Drug Delivery Volume IV: Transdermal and Transmucousal Drug Delivery Volume V: Advanced Drug Delivery This series segmented the market by technology and included an innovative analysis that estimated...